Valuation : Ocular Therapeutix, Inc.

Market Cap 2.5B 2.15B 2.02B 1.84B 3.45B 238B 3.46B 23.98B 9.27B 121B 9.38B 9.17B 383B P/E 2026 *
-7.63x
P/E 2027 * -8.16x
Enterprise Value 2.12B 1.82B 1.72B 1.56B 2.93B 202B 2.94B 20.35B 7.86B 103B 7.96B 7.78B 325B EV / Sales 2026 *
40x
EV / Sales 2027 * 23.7x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Ocular Therapeutix, Inc.

1 day-0.40%
1 week+4.04%
Current month+8.10%
1 month+22.73%
3 months+33.89%
6 months+14.09%
Current year-6.59%
1 week 10.4
Extreme 10.4
11.46
1 month 9.04
Extreme 9.04
11.74
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Sell

Chief Operating Officer

-1,099 0.0005%
25/8/26 Don

Chief Executive Officer

-100,184 0.0473%
24/8/26 Sell

Executive/Senior Manager

-3,035 0.0014%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+4.04%-11.13%+192.27% 2.5B
+0.10%-2.99%+49.94%+88.97% 1,002B
-0.36%-2.52%+51.60%+64.93% 649B
+0.78%-4.49%+18.79%+67.71% 440B
-0.80%-0.43%+28.92%+36.94% 346B
-0.13%-14.97%+9.41%+26.44% 263B
-1.90%-2.72%-2.72%+10.93% 250B
-0.20%-11.66%+39.73%+49.48% 213B
-1.06%-4.23%-14.70%-57.76% 201B
-0.52%-2.59%+25.90%+89.17% 182B
Average -0.44%-1.10%+19.57%+56.91% 354.62B
Weighted average by Cap. -0.27%-2.38%+32.07%+56.14%

Financials

2026 *2027 *
Net sales 52.93M 45.54M 42.88M 39.07M 73.11M 5.04B 73.4M 508M 196M 2.57B 199M 194M 8.13B 102M 88.18M 83.03M 75.65M 142M 9.75B 142M 984M 380M 4.97B 385M 376M 15.74B
Net income -334M -288M -271M -247M -462M -31.81B -464M -3.21B -1.24B -16.21B -1.26B -1.23B -51.34B -324M -279M -263M -239M -448M -30.87B -450M -3.12B -1.2B -15.73B -1.22B -1.19B -49.82B
Net Debt -378M -325M -306M -279M -522M -35.97B -524M -3.63B -1.4B -18.32B -1.42B -1.39B -58.05B -66M -56.79M -53.48M -48.73M -91.17M -6.28B -91.53M -634M -245M -3.2B -248M -242M -10.14B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
10/09/26 USD 11.36 -0.13% 1,847,143
08/09/26 USD 11.37 +6.86% 2,737,328
04/09/26 USD 10.64 0.00% 1,306,871
03/09/26 USD 10.64 -2.39% 2,128,709
02/09/26 USD 10.90 +3.12% 2,068,790
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
11.37USD
Average target price
27.09USD
Spread / Average Target
+138.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!